Search Results

You are looking at 21 - 30 of 447 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Ryan D. Gentzler and Jyoti D. Patel

became available for the treatment of NSCLC. The large phase III ECOG 1594 trial randomized 1155 patients with advanced NSCLC with a performance status (PS) of 0 to 2 to a reference regimen of cisplatin and paclitaxel versus 3 other platinum

Full access

Ciara C. O'Sullivan, Holly K. Van Houten, Lindsey R. Sangaralingham, Alexis D. Leal, Shivani Shinde, Hongfang Liu, David Ettinger, Charles L. Loprinzi, and Kathryn J. Ruddy

This study analyzed preexisting, deidentified data, and was therefore deemed exempt from Institutional Review Board approval. Study Population We identified patients who initiated AC, TAC (paclitaxel or docetaxel with doxorubicin and

Full access

Kim Margolin

Einhorn LH . Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): A trial of the Eastern Cooperative Oncology Group . J Clin Oncol 2002 ; 20 : 1859 – 1863 . 18 Hartmann JT Schleucher N Metzner B . Phase I

Full access

David H. Moore

. Moore DH Blessing JA McQuellon RP . Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study . J Clin Oncol 2004 ; 22 : 3113 – 3119

Full access

Ashley E. Glode, S. Lindsey Davis, Supriya K. Jain, Megan D. Marsh, Lisa J. Wingrove, Tracey E. Schefter, Karyn Goodman, Lindel C.K. Dewberry, Martin D. McCarter, Laura Melton, Michelle Bunch, William T. Purcell, and Stephen Leong

, patients received an average of 5 chemotherapy treatments (range, 2–6), with an average relative dose intensity of 91.8% for carboplatin and 86.7% for paclitaxel. During the STRENGTH period, patients received an average of 6 (range, 5–8) chemotherapy

Full access

Amy A. Kirkham, Karen A. Gelmon, Cheri L. Van Patten, Kelcey A. Bland, Holly Wollmann, Donald C. McKenzie, Taryne Landry, and Kristin L. Campbell

only due to smaller sample sizes. The RR of a dose reduction or delay for doxorubicin, docetaxel, and paclitaxel was assessed independently. Cyclophosphamide was not assessed because it was exclusively administered concurrent to doxorubicin or docetaxel

Full access

paclitaxel (Taxol, Bristol-Myers Squibb Company) as an appropriate therapeutic option for metastatic breast cancer with the evidence designation 2A meaning that it is based on lower level evidence and uniform agreement of the panel as to its appropriateness

Full access

Amit Mahipal, Minsig Choi, and Richard Kim

to poor accrual. In the 40 patients studied, survival was significantly longer in the irinotecan arm (median OS, 4.0 vs 2.4 months). Tumor-related symptoms were significantly improved in the experimental arm. Other single agents, such as paclitaxel

Full access

Harold J. Burstein

provide confirmatory evidence supporting the original ECOG 2100 study that had led to accelerated approval of bevacizumab in combination with paclitaxel for advanced breast cancer. The FDA will decide in September whether to withdraw the label for the

Full access

Presenter: William J. Gradishar

are given earlier in the course of metastatic disease rather than later, he added. Less frequently, microsatellite instability–high (MSI-H) status can also be exploited with the anti–PD-L1 agent atezolizumab + nab-paclitaxel. The rate NTRK fusions